Fig. 4
Tumor-specific release of P1021 payload contributes to DB-1310 in vivo efficacy in the NCI-H441 model. NU/NU mice were subcutaneously inoculated with 5 × 106 NCI-H441 NSCLC cells and intravenously injected with either 1 or 5 mg/kg DB-1310. Serum and tumor samples were collected at different time points. Total antibody and ADC concentrations in serum were measured by ELISA (a). Free payload concentrations in serum and tumor samples were measured by LC-MS/MS (b). (c) The level of P-H2AX in tumors was measured by western blotting and normalized to β-actin